SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
SITC 2024 preview – duelling TIGIT duds
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
